Vitamin D

Vitamin D is worth fixing if you are low, and that is most of the story. Large trials in people who already had decent levels found no effect on cancer, heart disease or death. The exciting extras sold alongside it, such as slower aging, fewer autoimmune diseases and fewer cancer deaths, are weak leads at best.

If a blood test shows you are low, take D3 daily until you are back in range, then drop to the standard 600–800 IU a day (more from age 75). Between 30 and 50 nmol/L, take 2000 IU a day for 12 weeks; below 30 nmol/L, take 4000 IU a day for 8–12 weeks, then retest. If you are already in range and under 75, more than the standard intake has not been shown to help.

What the big trials found

In people who were not deficient, large randomised trials found that vitamin D did not lower deaths, cancer, or major heart and stroke events. The largest, VITAL, gave about 26,000 US adults 2000 IU a day for just over five years. It found no effect on its main targets, invasive cancer and major heart and stroke events, and no effect on death from any cause.[1] An Australian trial, D-Health, in about 21,000 older adults using a large monthly dose, was also null for death, with the estimate a fraction on the wrong side.[2]

These trials mostly enrolled people who were not deficient (D-Health's placebo group averaged 77 nmol/L), so they say less about people who are truly low. A 2026 modelling study in UK Biobank data projected about 20–25% lower mortality in deficient people.[3] That projection rests on observational data, not a trial.

The genetic evidence points the other way. An influential 2021 study that used genes to suggest vitamin D prevents deaths in deficient people was retracted in 2024 for invalid statistics. Republished with corrected methods across about 500,000 people, it found no causal link with death, heart disease or stroke at any level, including the deficient.[4] Low vitamin D is largely a marker of chronic illness, inactivity, obesity and less time outdoors. That is why the observational links look strong while the trials and genetics are flat.

Other outcomes tell the same story in people who were not deficient:

  • Fractures and falls. In VITAL, 2000 IU a day did not lower fractures.[5] A 2026 review of 69 trials and about 154,000 adults, mostly living at home and not at high risk, found vitamin D alone made no difference to fractures and little to none to falls; adding calcium gave at most a very small benefit.[6] The US Preventive Services Task Force advises against low-dose daily vitamin D with calcium (400 IU or less with 1,000 mg or less) to prevent fractures in postmenopausal women living at home.[7]
  • Depression. A trial in about 18,000 adults found no effect on new or recurring depression.[8]
  • Colds and chest infections. Pooling 40 trials and about 62,000 people, the odds of a respiratory infection were about 6% lower, small enough to be compatible with no effect. People who started out low did not benefit more.[9]
  • Heart disease. No large trial has clearly shown a benefit. D-Health saw a small drop in major heart and stroke events that was still compatible with no effect.[10] A trial in 630 heart-attack survivors made headlines in 2025 for halving repeat heart attacks, but its main combined outcome did not improve; the heart-attack result was a secondary finding, in people who had already had one.[11]

Diabetes is a partial exception. In people who already had prediabetes, pooled data from three trials showed about 15% lower risk of progressing to type 2 diabetes, roughly 3 fewer cases per 100 people over 3 years.[12] The trials used 4000 IU a day, 20,000 IU a week or a vitamin D drug. This has not been shown in people with normal blood sugar.

Cancer and autoimmune disease: leads that shrank

Two leads from the trials looked promising; one faded on longer follow-up, and neither is established.

Cancer deaths. In VITAL, cancer deaths were about 17% lower, a result compatible with no effect. Leaving out the first two years, they were about a quarter lower, but that analysis was not in the trial plan and is best treated as a lead.[13] A later look at advanced cancer pointed the same way, with the effect concentrated in people of normal weight and none seen in those with overweight or obesity.[14]

A 2023 pooled analysis of 14 trials and about 105,000 people found no clear overall drop in cancer deaths. In the 10 trials that dosed daily, cancer deaths were about 12% lower, while the 4 trials using large intermittent doses showed no benefit.[15] That is a subgroup finding, not proof. If real, it suggests steady levels matter more than total dose.

Autoimmune disease. In VITAL, people taking 2000 IU a day had about 22% fewer new autoimmune diagnoses over 5 years, a borderline result. Once late-confirmed cases were added, the benefit shrank to about 15% and was no longer statistically clear, and two years after people stopped there was no difference over the full 7 years.[16] Any protection seems to last only while you keep taking it, and may be smaller than first reported.

Aging: one small signal, and one that belongs to omega-3

The evidence that vitamin D slows aging itself is thin. Telomeres are the protective caps on chromosomes that shorten as cells divide. In a four-year substudy of about 1,000 VITAL participants, those on 2000 IU a day lost about 140 fewer base pairs of telomere than those on placebo, a borderline result.[17] Telomere length tracks real health outcomes only weakly. Across about 185,000 people in observational studies, the link between vitamin D and telomeres was weak and absent in men and in people already above 75 nmol/L.[18]

The "vitamin D slows aging clocks" claim comes from a Swiss-led trial of adults over 70 that missed all six of its main goals. A later, unplanned analysis of 777 participants looked at DNA-methylation aging clocks. Vitamin D alone changed none of the four clocks. Omega-3 alone slowed three of them: two by about 3 to 4 months over 3 years, the third by about 1% in pace, and adding vitamin D and exercise helped further on only one clock.[19] See Omega-3.

In a large US snapshot survey, an aging score built from routine blood tests was older with low vitamin D, but the link faded above about 38 nmol/L in men and 63 nmol/L in women, and men above about 92 nmol/L scored very slightly older.[20] Higher is not reliably better.

What level to aim for

Get out of deficiency and stop there. Correcting a real deficiency is well established, especially for bone; no higher target has been shown to help. The usual cutoffs follow the US National Academies' 2011 review, which found 50 nmol/L enough for almost everyone, no consistent extra benefit above 75 nmol/L, and reason for concern above 125 nmol/L.[21]

25(OH)D levelStatusAction
<30 nmol/L (<12 ng/mL)DeficientCorrect urgently
30–50 nmol/L (12–20 ng/mL)InsufficientSupplement
50–125 nmol/L (20–50 ng/mL)SufficientMaintain
>125 nmol/L (>50 ng/mL)HighReduce dose; recheck
>250 nmol/L (>100 ng/mL)Very highStop; check blood calcium

Severe deficiency is uncommon in healthy adults eating a mixed diet at lower latitudes; the "deficiency epidemic" of the 2010s was somewhat overstated. Insufficiency, 30–50 nmol/L, is common at higher latitudes in winter, and it is the gap supplements actually fill.

The 2024 Endocrine Society guideline found no clear evidence for any optimal blood level for preventing disease.[22] It advises healthy adults under 75 against taking more than the standard 600–800 IU a day. It does suggest extra vitamin D, without testing, for adults 75 and over (it may lower death risk), in pregnancy, for ages 1–18, and for people with high-risk prediabetes.

In one cohort of about 2,900 very old Chinese adults, death rates fell as levels climbed out of deficiency and levelled off above roughly 65 nmol/L.[23] A longevity camp argues for 100–150 nmol/L, but that rests on surrogate markers and subgroup findings, not hard outcomes. Aiming for roughly 50–125 nmol/L keeps you out of deficiency without chasing high numbers.

How to take it

Testing. To dose deliberately, test once in autumn or winter, when levels are lowest. It is not a routine screen: the Endocrine Society advises against routine testing, and the US Preventive Services Task Force says there is not enough evidence to judge whether screening people without symptoms helps.[24]

Dose by level.

  • 30–50 nmol/L: 2000 IU a day for 12 weeks, then retest.
  • Below 30 nmol/L: 4000 IU a day for 8–12 weeks, retest, then drop to the 600–800 IU a day standard intake (more from age 75).
  • 50 nmol/L or more: no extra benefit has been shown above the standard 600–800 IU a day in healthy adults under 75.
  • People with overweight or obesity get a noticeably smaller rise from the same dose, so if they are low they may need longer on the correction doses before retesting.[25]
  • Retest yearly at the end of winter once you have settled on a dose.

Form. Take D3 (cholecalciferol), not D2. D2 raises levels less reliably and seems to speed the clearance of the body's own D3.[26] A drop or softgel is fine. Calcifediol, a form that raises levels faster, is worth knowing about for malabsorption or when quick correction is needed.

Daily, not big occasional doses. An annual 500,000 IU dose raised falls by 15% and fractures by 26% in women aged 70 and over at high fracture risk; the extra falls were largest in the three months after each dose, in an unplanned analysis.[27] In D-Health, cancer deaths were about 15% higher, a result compatible with no effect (about 24% higher after leaving out the first two years, in an exploratory analysis),[28] though fractures[29] and new cancers did not rise.[30] Large intermittent doses are at best useless and at worst harmful.

With food, if convenient. A meal containing fat raised peak absorption by about a third compared with a fat-free meal.[31] But in another trial, blood levels one and three months later were the same with no meal, a low-fat meal or a high-fat meal.[32]

Magnesium helps activate vitamin D; check it only if your level won't rise on a sensible dose. See Magnesium.

Winter sun won't do it. Beyond about 40° latitude, north or south, the skin cannot make vitamin D for part of the year: roughly November to February at 42°, and October to March at 52°.[33] [34] Stores last only weeks, so a sunny summer cannot cover the winter. For the wider case for sunlight, see Sun exposure.

Adding vitamin K2

Vitamin D raises calcium absorption; vitamin K2 (MK-7) activates proteins that steer calcium into bone rather than arteries. The pairing makes biological sense, but the trials are thin and mixed. In people with heavy coronary calcification, 720 µg of MK-7 plus 1000 IU of D3 a day slowed calcium build-up in the heart arteries by about a fifth over two years compared with placebo.[35] The same regimen in older men with calcified aortic valves did nothing.[36] No trial has shown fewer fractures, heart attacks or deaths, and neither compared the pair with D3 alone.

If you want it, 90–180 µg of MK-7 a day alongside D3 is reasonable, far below the trial dose. See Vitamin K2 and Bone density.

Who should be careful

  • Above 4000 IU a day for months. That is the official upper limit, a cautious ceiling below the 10,000 IU a day level not linked to high blood calcium.[37] In a 3-year trial in healthy 55–70-year-olds, mildly high blood calcium appeared in 3% on 4000 IU and 9% on 10,000 IU (none on 400 IU), all temporary, while high urine calcium was common in every group.[38] Both high doses left forearm bone density slightly lower than 400 IU, with no difference in bone strength.[39] If you take that much, check blood calcium and 25(OH)D. Real toxicity is rare from supplements but happens with years of megadosing.
  • Granuloma-forming diseases (sarcoidosis, some lymphomas, tuberculosis) can disturb vitamin D handling. Work with a clinician.
  • Warfarin users taking K2: vitamin K counteracts warfarin, so coordinate with your prescriber.
  • Calcium supplements carry their own risks; calcium from food does not show the same heart signal. See Supplements to avoid.

Further reading

  • Manson JE et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL). NEJM 2019.[40]
  • Neale RE et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes & Endocrinology 2022.[41]
  • Emerging Risk Factors Collaboration / EPIC-CVD / Vitamin D Studies Collaboration. Retraction and republication — Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality. Lancet Diabetes & Endocrinology 2024.[42]
  • Demay MB et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2024.[43]
  • Kuznia S et al. Efficacy of vitamin D3 supplementation on cancer mortality: systematic review and individual patient data meta-analysis. Ageing Research Reviews 2023.[44]
  • Costenbader KH et al. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis & Rheumatology 2024.[45]
  • Pittas AG et al. Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes: A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Annals of Internal Medicine 2023.[46]
  • Bischoff-Ferrari HA et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging (DO-HEALTH). Nature Aging 2025.[47]
  • Zhu H et al. Vitamin D3 and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL). Am J Clin Nutr 2025.[48]
  • May HT et al. Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial. European Heart Journal 2026.[49]
  • Sanders KM et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women. JAMA 2010.[50]
— § —